Grufity logo
Grufity logo
ATNF

ATNF - 180 Life Sciences Corp. Stock Price, Fair Value and News

$16.80+0.10 (+0.60%)
Market Closed as of 17 Oct 2025, 04:00 pm ET

Price Targets

ATNF Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ATNF Price Action

Last 7 days

748.5%

Last 30 days

633.6%

Last 90 days

793.6%

Trailing 12 Months

288.0%

ATNF RSI Chart

ATNF Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ATNF Valuation

Market Cap

244.3M

Price/Earnings (Trailing)

-0.47

Price/Sales (Trailing)

37.32

EV/EBITDA

-1.3

Price/Free Cashflow

-7.48

ATNF Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ATNF Fundamentals

ATNF Revenue

Revenue (TTM)

6.5M

Rev. Growth (Qtr)

-12.73%

ATNF Earnings

Earnings (TTM)

-524.4M

Earnings Growth (Yr)

-3.1K%

Earnings Growth (Qtr)

66.8%

ATNF Profitability

EBT Margin

-7931.56%

Return on Equity

-311.53%

Return on Assets

-252.6%

Free Cashflow Yield

-13.38%

ATNF Investor Care

Shares Dilution (1Y)

5884.24%

Diluted EPS (TTM)

-22.59

Revenue & Growth

How 180 Life Sciences Corp. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
20252.3M-3.7M5.1M
20243.1M2.5M2.0M1.4M
20235.2M-4.4M3.6M
2022---5.9M
20205.4M5.7M--
20194.3M4.5M4.8M5.1M
20181.0M1.3M1.7M2.0M
2017---663.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About 180 Life Sciences Corp.

ATNF
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
 CEO
 WEBSITEhttps://180lifesciences.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES5

180 Life Sciences Corp. Frequently Asked Questions

ATNF is the stock ticker symbol of 180 Life Sciences Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Apr 30 2026, market cap of 180 Life Sciences Corp. is 244.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Thu Apr 30 2026, ATNF's PE ratio (Price to Earnings) is -0.47 and Price to Sales (PS) ratio is 37.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATNF PE ratio will change depending on the future growth rate expectations of investors.